Mar Mallo
YOU?
Author Swipe
View article: The multiomics blueprint of the individual with the most extreme lifespan
The multiomics blueprint of the individual with the most extreme lifespan Open
Extreme human lifespan, exemplified by supercentenarians, presents a paradox in understanding aging: despite advanced age, they maintain relatively good health. To investigate this duality, we have performed a high-throughput multiomics st…
View article: A Murine Model of Glioblastoma Initiating Cells and Human Brain Organoid Xenograft for Photodynamic Therapy Testing
A Murine Model of Glioblastoma Initiating Cells and Human Brain Organoid Xenograft for Photodynamic Therapy Testing Open
Glioblastoma (GB) is one of the most aggressive brain tumors, characterized by high infiltrative capacity that enables tumor cells to invade healthy brain tissue and evade complete surgical resection. This invasiveness contributes to resis…
View article: Integrated cytogenetic and genomic profiling of the MDS-L cell line
Integrated cytogenetic and genomic profiling of the MDS-L cell line Open
Among the human leukemia cell lines described in the literature, only the MDS-L cell line has been definitively established from a patient during the myelodysplastic syndrome (MDS) phase of the disease. However, the limited studies on its …
View article: The Multiomics Blueprint of Extreme Human Lifespan
The Multiomics Blueprint of Extreme Human Lifespan Open
The indexed individual, from now on termed M116, was the world's oldest verified living person from January 17th 2023 until her passing on August 19th 2024, reaching the age of 117 years and 168 days (https://www.supercentenarian.com/recor…
View article: Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib
Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib Open
We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) pot…
View article: Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Open
INTRODUCTION Acquired regions of homozygosity (aROHs) detected along the human genome are due to mitotic recombination between homologous chromosomes. This mechanism may contribute to the growth of a neoplastic clone if the involved region…
View article: The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation
The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation Open
The aim of this study was to determine how TERTp mutations impact glioblastoma prognosis. Materials and Methods: TERTp mutations were assessed in a retrospective cohort of 258 uniformly treated glioblastoma patients. RNA-sequencing and who…
View article: A framework for the clinical implementation of optical genome mapping in hematologic malignancies
A framework for the clinical implementation of optical genome mapping in hematologic malignancies Open
Optical Genome Mapping (OGM) is rapidly emerging as an exciting cytogenomic technology both for research and clinical purposes. In the last 2 years alone, multiple studies have demonstrated that OGM not only matches the diagnostic scope of…
View article: Optical genome mapping: technical basis and applications in hematological malignancies
Optical genome mapping: technical basis and applications in hematological malignancies Open
Cytogenomic analyses of hematological malignancies require the use of different techniques, whether combined or on isolation, for the detection of chromosomal abnormalities.Optical genomic mapping (OGM) is a new technology based on the ana…
View article: Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing
Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing Open
Introduction: myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases. Morphologic bone marrow (BM) examination, cytogenetic analysis and molecular techniques are indispensable for accurate diagnosis and disease…
View article: Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Representative images comparing high versus low immunohistochemical expression of (A,B) EGFR,(C,D) PTEN, (E,F) SOX-2, (G,H) SHC1, (I,J) TCIRG1,(K,L) IDH1R132H (K:positive, L: negative), (M,N) Olig2,and (O,P) Ki67
View article: Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S4 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Representative images comparing high versus low immunohistochemical expression of (A,B) EGFR,(C,D) PTEN, (E,F) SOX-2, (G,H) SHC1, (I,J) TCIRG1,(K,L) IDH1R132H (K:positive, L: negative), (M,N) Olig2,and (O,P) Ki67
View article: Data from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Data from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Purpose:Molecular subtype classifications in glioblastoma may detect therapy sensitivities. IHC would potentially allow the identification of molecular subtypes in routine clinical practice.Experimental Design:Formalin-fixed, paraffin-embe…
View article: Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Statistically significant adjusted P-values for differential expression of genes in the pairwise comparison of molecular subtypes. Two of these genes were selected for immunohistochemical analysis for the identification of the mesenchymal …
View article: Supplementary Fig. S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
IHC protein expression of IDH1, EGFR (intensity 3 as high versus 0-2), high intensity, PTEN, OLIG2, Ki67 and SOX2 by IGS (first row) and TCGA subtype (second row: KNN, third row: SVM, fourth row: ssGSEA). Significant differences were seen …
View article: Supplementary Fig S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
In 38 sequenced samples classified according to the Support Vector Machine (SVM) algorithm, heatmaps were plotted to compare the expression of the top 50 genes between (A) classical and mesenchymal, (B) mesenchymal and proneural, and (C) c…
View article: Data from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Data from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Purpose:Molecular subtype classifications in glioblastoma may detect therapy sensitivities. IHC would potentially allow the identification of molecular subtypes in routine clinical practice.Experimental Design:Formalin-fixed, paraffin-embe…
View article: Supplementary Fig. S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Spearman correlation between gene and protein expression for the four antibodies selected according to RNA-Seq differential expression.
View article: Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Key resource identifiers (RRIDs), antibodies, methods, and scoring systems used for immunohistochemistry analyses
View article: Supplementary Table S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Table S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Patient characteristics and molecular subtypes
View article: Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Statistically significant adjusted P-values for differential expression of genes in the pairwise comparison of molecular subtypes. Two of these genes were selected for immunohistochemical analysis for the identification of the mesenchymal …
View article: Supplementary Fig. S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Spearman correlation between gene and protein expression for the four antibodies selected according to RNA-Seq differential expression.
View article: Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Key resource identifiers (RRIDs), antibodies, methods, and scoring systems used for immunohistochemistry analyses
View article: Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Excel spreadsheets showing: (S1a) the differential expression analysis between mesenchymal vs proneural tumors; (S1b) the differential expression analysis between classical vs mesenchymal tumors; (S1c) the differential expression analysis …
View article: Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Data files S1 a_f from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Excel spreadsheets showing: (S1a) the differential expression analysis between mesenchymal vs proneural tumors; (S1b) the differential expression analysis between classical vs mesenchymal tumors; (S1c) the differential expression analysis …
View article: Supplementary Table S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Table S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
Patient characteristics and molecular subtypes
View article: Supplementary Fig S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
In 38 sequenced samples classified according to the Support Vector Machine (SVM) algorithm, heatmaps were plotted to compare the expression of the top 50 genes between (A) classical and mesenchymal, (B) mesenchymal and proneural, and (C) c…
View article: Supplementary Fig. S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Supplementary Fig. S3 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy Open
IHC protein expression of IDH1, EGFR (intensity 3 as high versus 0-2), high intensity, PTEN, OLIG2, Ki67 and SOX2 by IGS (first row) and TCGA subtype (second row: KNN, third row: SVM, fourth row: ssGSEA). Significant differences were seen …
View article: Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype
Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype Open
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20–30% with the complementary application of genomic microarrays. We here p…